Acute renal problems in the critically ill cancer patient

Current Opinion in Critical Care

Volumn 14, Issue 6, 2008, Pages 635-646

  Lameire, Norbert ^a   Van Biesen, Wim ^a   Vanholder, Raymond ^a  

^a GHENT UNIVERSITY HOSPITAL   (Belgium)

Author keywords

Acute kidney injury; Acute kidney problems and oncology; Critically ill cancer patients; Malignancies

Indexed keywords

ALLOPURINOL; BISPHOSPHONIC ACID DERIVATIVE; BLEOMYCIN; CISPLATIN; CYCLOPHOSPHAMIDE; DIURETIC AGENT; GEMCITABINE; IBANDRONIC ACID; IFOSFAMIDE; METHOTREXATE; MITOMYCIN C; PAMIDRONIC ACID; PLATINUM DERIVATIVE; RASBURICASE; URATE OXIDASE; ZOLEDRONIC ACID;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE KIDNEY FAILURE; ACUTE LYMPHOCYTIC LEUKEMIA; ALBUMINURIA; ARTIFICIAL VENTILATION; BONE MARROW TRANSPLANTATION; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER SCREENING; CREATININE CLEARANCE; CRITICALLY ILL PATIENT; EDEMA; ELECTROLYTE DISTURBANCE; ELECTROLYTE METABOLISM; ENTERIC FEEDING; FOLLOW UP; GLOMERULONEPHRITIS; GLOMERULUS FILTRATION RATE; GRAFT VERSUS HOST REACTION; HEAD AND NECK CANCER; HEMATOLOGIC MALIGNANCY; HEMOLYTIC UREMIC SYNDROME; HUMAN; HYPERCALCEMIA; INCIDENCE; INTENSIVE CARE UNIT; KIDNEY DISEASE; KIDNEY FUNCTION; MULTIPLE MYELOMA; NEPHROTOXICITY; PARENTERAL NUTRITION; PROTEINURIA; REFEEDING SYNDROME; REVIEW; SEPSIS; STEM CELL TRANSPLANTATION; TUMOR LYSIS SYNDROME; URINALYSIS; VASCULITIS;

CRITICAL ILLNESS; ELECTROLYTES; GLOMERULAR FILTRATION RATE; GLOMERULONEPHRITIS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; KIDNEY FAILURE, ACUTE; NEOPLASMS; TUMOR LYSIS SYNDROME; UNITED STATES;

EID: 57149104131     PISSN: 10705295     EISSN: 15317072     Source Type: Journal    
DOI: 10.1097/MCC.0b013e32830ef70b     Document Type: Review

References (90)

1. Lameire NH, Flombaum CD, Moreau D, Ronco C. Acute renal failure in cancer patients. Ann Med 2005; 37:13-25.
2. Stevens LA, Coresh J, Greene T, Levey AS. Assessing kidney function: measured and estimated glomerular filtration rate. N Engl J Med 2006; 354:2473-2483.
3. Murthy K, Stevens LA, Stark PC, Levey AS. Variation in the serum creatinine assay calibration: a practical application to glomerular filtration rate estimation. Kidney Int 2005; 68:1884-1887.
4. Dash A, Galsky MD, Vickers AJ, et al. Impact of renal impairment on eligibility for adjuvant cisplatin-based chemotherapy in patients with urothelial carcinoma of the bladder. Cancer 2006; 107:506-513.
5. Murray PT, Ratain MJ. Estimation of the glomerular filtration rate in cancer patients: a new formula for new drugs. J Clin Oncol 2003; 21:2633-2635.
6. Wright JG, Boddy AV, Highley M, et al. Estimation of glomerular filtration rate in cancer patients. Br J Cancer 2001; 84:452-459.
7. Marx GM, Blake GM, Galani E, et al. Evaluation of the Cockroft-Gault, Jelliffe and Wright formulae in estimating renal function in elderly cancer patients. Ann Oncol 2004; 15:291-295.
8. Poole SG, Dooley MJ, Rischin D. A comparison of bedside renal function estimates and measured glomerular filtration rate (Tc99mDTPA clearance) in cancer patients. Ann Oncology 2002; 13:949-955.
9. Monfardini S. Evaluation of renal function in elderly cancer patients. Ann Oncol 2004; 15:183-184.
10. Benohr P, Grenz A, Hartmann JT, et al. Cystatin C- a marker for assessment of glomerular filtration rate in patients with cisplatin chemotherapy. Kidney Blood Press Res 2006; 29:32-35.
11. Holweger K, Bokemeyer C, Lipp HP. Accurate assessment of individual glomerular filtration rate in cancer patients: an ongoing challenge. J Cancer Res Clin Oncol 2005; 131:559-567.
12. Seronie-Vivien S, Toullec S, Malard L, et al. Contribution of the MDRD equation and of cystatin C for renal function estimates in cancer patients. Med Oncol 2006; 23:63-73.
13. Bokenkamp A, Laarman CA, Braam KI, et al. Effect of corticosteroid therapy on low-molecular weight protein markers of kidney function. Clin Chem 2007; 53:2219-2221.
14. Demirtas S, Akan O, Can M, et al. Cystatin C can be affected by nonrenal factors: a preliminary study on leukemia. Clin Biochem 2006; 39:115-118.
15. Mulaomerovic A, Halilbasic A, Cickusic E, et al. Cystatin C as a potential marker for relapse in patients with non-Hodgkin B-cell lymphoma. Cancer Lett 2007; 248:192-197.
16. Tumminello FM, Badalamenti G, Incorvaia L, et al. Serum interleukin-6 in patients with metastatic bone disease: correlation with cystatin C. Med Oncol 2008 [Epub ahead of print].
17. Macdonald J, Marcora S, Jibani M, et al. GFR estimation using cystatin C is not independent of body composition. Am J Kidney Dis 2006; 48:712-719.
18. Herget-Rosenthal S, Bokenkamp A, Hofmann W. How to estimate GFR: serum creatinine, serum cystatin C or equations? Clin Biochem 2007; 40:153-161.
19. Zahran A, El-Husseini A, Shoker A. Can cystatin C replace creatinine to estimate glomerular filtration rate? A literature review. Am J Nephrol 2007; 27:197-205.
20. Launay-Vacher V, Izzedine H, Rey JB, et al. Incidence of renal insufficiency in cancer patients and evaluation of information available on the use of anticancer drugs in renally impaired patients. Med Sci Monit 2004; 10:CR209-CR212.
21. Dogan E, Izmirli M, Ceylan K, et al. Incidence of renal insufficiency in cancer patients. Adv Ther 2005; 22:357-362.
22. Wetzels JF, Kiemeney LA, Swinkels DW, et al. Age- and gender-specific reference values of estimated GFR in Caucasians: the Nijmegen Biomedical Study. Kidney Int 2007; 72:632-637.
23. Levey AS, Eckardt KU, Tsukamoto Y, et al. Definition and classification of chronic kidney disease: a position statement from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int 2005; 67:2089-2100.
24. Levey AS, Atkins R, Coresh J, et al. Chronic kidney disease as a global public health problem: approaches and initiatives - a position statement from Kidney Disease Improving Global Outcomes. Kidney Int 2007; 72:247-259.
25. Spinazze S, Schrijvers D. Metabolic emergencies. Crit Rev Oncol Hematol 2006; 58:79-89.
26. Lameire N. The kidney in oncology. Acta Clin Belg 2007; 62:141-154.
27. Renneboog B, Decaux G. Idiopathic hyponatremia in a young patient: look at the sinus. Am J Med 2008; 121 :e5-e6.
28. Onitilo AA, Kio E, Doi SA. Tumor-related hyponatremia. Clin Med Res 2007; 5:228-237.
29. Raftopoulos H. Diagnosis and management of hyponatremia in cancer patients. Support Care Cancer 2007; 15:1341-1347.
30. Lehrich RW, Greenberg A. When is it appropriate to use vasopressin receptor antagonists? J Am Soc Nephrol 2008; 19:1054-1058.
31. Soupart A, Gross P, Legros J-J, et al. Successful long-term treatment of hyponatremia in syndrome of inappropriate antidiuretic hormone secretion with satavaptan (SR 121463B), an orally active nonpeptide vasopressin V2-receptor antagonist. Clin J Am Soc Nephrol 2006; 1:1154-1160.
32. Zeltser D, Rosansky S, van RH, et al. Assessment of the efficacy and safety of intravenous conivaptan in euvolemic and hypervolemic hyponatremia. Am J Nephrol 2007; 27:447-457.
33. Filippatos TD, Milionis HJ, Elisaf MS. Alterations in electrolyte equilibrium in patients with acute leukemia. Eur J Haematol 2005; 75:449-460.
34. Olgar S, Yetgin S, Cetin M, et al. Electrolyte abnormalities at diagnosis of acute lymphocytic leukemia may be a clue for renal damage in long-term period. J Pediatr Hematol Oncol 2005; 27:202-206.
35. Hoorn EJ, Zietse R. Combined renal tubular acidosis and diabetes insipidus in hematological disease. Nat Clin Pract Nephrol 2007; 3:171-175.
36. Newman EM, Bouvet M, Borgehi S, et al. Causes of hypercalcemia in a population of military veterans in the United States. Endocr Pract 2006; 12:535-541.
37. Lee C-T, Yang C-C, Lam K-K, et al. Hypercalcemia in the emergency department. Am J Med Sci 2006; 331:119-123.
38. Finkel KW, Foringer JR. Renal disease in patients with cancer. Nat Clin Pract Nephrol 2007; 3:669-678. An excellent review of the topic covering most recent data.
39. Lumachi F, Brunello A, Roma A, Basso U. Medical treatment of malignancy-associated hypercalcemia. Curr Med Chem 2008; 15:415-421.
40. Marinella MA. Refeeding syndrome in cancer patients. Int J Clin Pract 2008; 62:460-465. A complete overview of this rarely discussed topic.
41. Clarkson MR, Friedewald JJ, Eustace JA, Rabb H. Acute kidney injury. In: Brenner BM, editor. Brenner & Rector's the kidney, 8th ed. Philadelphia: Saunders & Elsevier; 2008. pp. 943-986.
42. Kellum JA, Levin N, Bouman C, Lameire N. Developing a consensus classification system for acute renal failure. Curr Opin Crit Care 2002; 8:509-514.
43. Molitoris BA, Levin A, Warnock DG, et al. Improving outcomes of acute kidney injury: report of an initiative. Nat Clin Pract Nephrol 2007; 3:439-442.
44. Bagshaw SM, George C, Bellomo R. A comparison of the RIFLE and AKIN criteria for acute kidney injury in critically ill patients. Nephrol Dial Transplant 2008; 23:1569-1574.
45. Kellum JA. Defining and classifying AKI: one set of criteria. Nephrol Dial Transplant 2008; 23:1471-1472.
46. Lameire N, Vanholder R, Van Biesen W. Loop diuretics for patients with acute renal failure: helpful or harmful? JAMA 2002; 288:2599-2601.
47. Joannidis M, Metnitz PG. Epidemiology and natural history of acute renal failure in the ICU. Crit Care Clin 2005; 21:239-249.
48. Lameire N, Van Biesen W, Vanholder R. The changing epidemiology of acute renal failure. Nat Clin Pract Nephrol 2006; 2:364-377.
49. Darmon M, Ciroldi M, Thiery G, et al. Clinical review: specific aspects of acute renal failure in cancer patients. Crit Care 2006; 10:211-217.
50. Bagshaw SM, Laupland KB, Doig CJ, et al. Prognosis for long-term survival and renal recovery in critically ill patients with severe acute renal failure: a population-based study. Crit Care 2005; 9:R700-R709.
51. Benoit DD, Hoste EA, Depuydt PO, et al. Outcome in critically ill medical patients treated with renal replacement therapy for acute renal failure: comparison between patients with and those without haematological malignancies. Nephrol Dial Transplant 2005; 20:552-558.
52. Bagshaw SM, George C, Bellomo R. Changes in the incidence and outcome for early acute kidney injury in a cohort of Australian intensive care units. Crit Care 2007; 11:R68.
53. Bailey D, Phan V, Litauen C, et al. Risk factors of acute renal failure in critically ill children: a prospective descriptive epidemiological study. Pediatr Crit Care Med 2007; 8:29-35.
54. Bagshaw SM, Uchino S, Bellomo R, et al. Septic acute kidney injury in critically ill patients: clinical characteristics and outcomes. Clin J Am Soc Nephrol 2007; 2:431-439.
55. Uchino S, Kellum JA, Bellomo R, et al. Acute renal failure in critically ill patients: a multinational, multicenter study. JAMA 2005; 294:813-818.
56. Thomas KW. Reevaluating prognosis: cancer, septic shock, and changing outcomes. Crit Care Med 2008; 36:987-988. An interesting paper on the changing prognostic aspects of critically ill cancer patients.
57. Pene F, Percheron S, Lemiale V, et al. Temporal changes in management and outcome of septic shock in patients with malignancies in the intensive care unit. Crit Care Med 2008; 36:690-696.
58. Vandijck DM, Benoit DD, Depuydt PO, et al. Impact of recent intravenous chemotherapy on outcome in severe sepsis and septic shock patients with hematological malignancies. Intensive Care Med 2008; 34:847-855.
59. Pene F, Scares M. Can we still refuse ICU admission of patients with hematological malignancies? Intensive Care Med 2008; 34:790-792.
60. Lameire N, Van Biesen W, Vanholder R. Acute renal failure. Lancet 2005; 365:417-430.
61. Lameire N, Van Biesen W, Vanholder R. Epidemiology, clinical evaluation, and prevention of acute renal failure. In: Feehally J, Floege J, Johnson RJ, editors. Comprehensive clinical nephrology, 3rd ed. Philadelphia, USA: Mosby-Elsevier; 2007pp. 771-785.
62. de Jonge MJ, Verweij J. Renal toxicities of chemotherapy. Semin Oncol 2006; 33:68-73.
63. Isnard-Bagnis C, Decay Q. Anticancer drugs. In: De Broe ME, Porter GA, Bennett WM, Verpooten GA, editors. Clinical nephrotoxins, 2nd ed. Dordrecht: Kluwer Academic Publishers; 2003 pp. 353-372.
64. Safirstein RL. Renal diseases induced by antineoplastic agents. In: Schrier RW, editor. Diseases of the kidney and urinary tract, 8th ed. Philadelphia: Welters Kluwer; Lippincott Williams & Wilkins; 2007. pp. 1068-1081.
65. Launay-Vacher V, Rey JB, Isnard-Bagnis C, et al. Prevention of cisplatin nephrotoxicity: state of the art and recommendations from the European Society of Clinical Pharmacy Special Interest Group on Cancer Care. Cancer Chemother Pharmacol 2008; 61:903-909.
66. Barrett BJ, Parfrey PS. Clinical practice. Preventing nephropathy induced by contrast medium. N Engl J Med 2006; 354:379-386.
67. McCullough PA, Stacul F, Becker CR, et al. Contrast-Induced Nephropathy (CIN) Consensus Working Panel: executive summary. Rev Cardiovasc Med 2006; 7:177-197.
68. Pannu N, Wiebe N, Tonelli M. Prophylaxis strategies for contrast-induced nephropathy. JAMA 2006; 295:2765-2779.
69. McCarthy CS, Becker JA. Multiple myeloma and contrast media. Radiology 1992; 183:519-521.
70. Darmon M, Thiery G, Ciroldi M, et al. Intensive care in patients with newly diagnosed malignancies and a need for cancer chemotherapy. Crit Care Med 2005; 33:2488-2493.
71. Soares M, Salluh JI, Carvalho MS, et al. Prognosis of critically ill patients with cancer and acute renal dysfunction. J Clin Oncol 2006; 24:4003-4010.
72. Perez Valdivieso Jr, Bes-Rastrollo M, Monedero P, et al. Serum C-reactive protein on the prognosis of oncology patients with acute renal failure: an observational cohort study. Arch Med Res 2008; 39:326-331.
73. Liano F, Garcia-Martin F, Gallego A, et al. Easy and early prognosis in acute tubular necrosis: a forward analysis of 228 cases. Nephron 1989; 51:307-313.
74. Humphreys BD, Soiffer RJ, Magee CC. Renal failure associated with cancer and its treatment: an update. J Am Soc Nephrol 2005; 16:151-161.
75. Parikh CR, Sandmaier BM, Storb RF, et al. Acute renal failure after non-myeloablative hematopoietic cell transplantation. J Am Soc Nephrol 2004; 15:1868-1876.
76. Parikh CR, Yarlagadda SG, Storer B, et al. Impact of acute kidney injury on long-term mortality after nonmyeloablative hematopoietic cell transplantation. Biol Blood Marrow Transplant 2008; 14:309-315. The study describes the long-term prognosis of patients after HCT complicated by AKI.
77. Weiss AS, Sandmaier BM, Storer B, et al. Chronic kidney disease following nonmyeloablative hematopoietic cell transplantation. Am J Transplant 2006; 6:89-94.
78. Liu H, Ding JH, Liu BC, et al. Early renal injury after nonmyeloablative allogeneic peripheral blood stem cell transplantation in patients with chronic myelocytic leukemia. Am J Nephrol 2007; 27:336-341.
79. Hingorani SR, Guthrie K, Batchelder A, et al. Acute renal failure after myeloablative hematopoietic cell transplant: incidence and risk factors. Kidney Int 2005; 67:272-277.
80. Kersting S, Koomans HA, Hene RJ, Verdonck LF. Acute renal failure after allogeneic myeloablative stem cell transplantation: retrospective analysis of incidence, risk factors and survival. Bone Marrow Transplant 2007; 39:359-365.
81. Hochberg J, Cairo MS. Tumor lysis syndrome: current perspective. Haematologica 2008; 93:9-13.
82. Rampello E, Fricia T, Malaguarnera M. The management of tumor lysis syndrome. Nat Clin Pract Oncol 2006; 3:438-447.
83. Mukherjee E, Mukherji D, Jayawardene SA, Kon SP. Tumor lysis syndrome and acute renal failure: an increasing spectrum of presentations. Clin Nephrol 2007; 68:186-189.
84. Irish AB. Myeloma and the kidney. In: Feehally J, Floege J, Johnson RJ, editors. Comprehensive clinical nephrology, 3rd ed. Philadelphia: Mosby Elsevier; 2007. pp. 717-723.
85. Murphy SW, Barrett BJ, Parfrey PS. Contrast nephropathy. J Am Soc Nephrol 2000; 11:177-182.
86. Clark WF, Stewart AK, Rock GA, et al. Plasma exchange when myeloma presents as acute renal failure: a randomized, controlled trial. Ann Intern Med 2005; 143:777-784.
87. Clark WF, Garg AX. Plasma exchange for myeloma kidney: cast(s) away? Kidney Int 2008; 73:1211-1213.
88. Hutchison CA, Cockwell P, Reid S, et al. Efficient removal of immunoglobulin free light chains by hemodialysis for multiple myeloma: in vitro and in vivo studies. J Am Soc Nephrol 2007; 18:886-895. Promising, but preliminary, data on new dialysis strategies using high permeable membranes in patients with multiple myeloma.
89. Appel G, Radhakrishnan J, D'Agati V. Secondary glomerular disease. In: Brenner BM, editor. Brenner & Rector's the kidney, 8th ed. Philadelphia: Saunders Elsevier; 2008. pp. 1067-1146.
90. Pankhurst T, Savage CO, Gordon C, Harper L. Malignancy is increased in ANCA-associated vasculitis. Rheumatology (Oxford) 2004; 43:1532-1535.